Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK Study: Dosing Strategies for CDK4/6 Inhibitors in Older Patients with Metastatic Breast Cancer
NCT06377852Phase 3Recruiting
- Sponsor
- American Society of Clinical Oncology
- Start
- Oct 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of palbociclib, ribociclib in breast cancer, sponsored by American Society of Clinical Oncology. Started Oct 2024; status: recruiting.
02
Drugs
palbociclibribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06377852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377852.